6.3.1.4 GLP-1 RA (glutide) & GLP1-RA/GIP
*Please see information under each individual drug monograph below for further preparation specific information.*
Please prescribe GLP-1 RAs by brand, for licensed indications only (prescribing for off-label indications remains as not recommended or supported by Kent and Medway ICB), and ensure that quantities prescribed are appropriate - please follow standard guidelines on prescribing quantities.
As per the update on the SPS Medicines Supply Tool ( https://www.sps.nhs.uk/shortages/shortage-of-glp-1-receptor-agonists-semaglutide-dulaglutide-liraglutide-exenatide/ ), Exenatide (Bydureon BCise®) 2mg/0.85ml prolonged-release pre-filled pens remain available for patients stabilised on therapy but are not able to support new patient initiations. Bydureon Bcise® is licensed in the UK for use in type 2 diabetes only.
Exenatide (Byetta®) 5micrograms/0.02ml and 10micrograms/0.04ml pre-filled pens were discontinued at the end of March 2024
NHS Kent and Medway Integrated Care Board (ICB) does not support the off-label use (including weight loss) of Ozempic or other GLP-1 (glucagon-like peptide 1) receptor agonists (GLP-1 RAs) outside of product licenses.
At this time, it is imperative that all GLP-1 RAs (prescribed by brand) are ONLY prescribed for the treatment and management of type 2 diabetes. This is in the interest of patient safety for existing patients already on these medications.
For information on Wegovy (semaglutide) and Saxenda (liraglutide)in obesity Click Here
Tirzepatide (Mounjaro ®) Fact Sheet Click Here
Trulicity® is licensed in the UK for use in type 2 diabetes only – do not prescribe solely for weight loss. For Trulicity®: for once weekly dosing, four pens (4 doses) = one month’s supply
| Pack |
|---|
| 4 pre-filled disposable injection |
| Pack |
|---|
| 4 pre-filled disposable injection |
As per the update on the SPS Medicines Supply Tool (https://www.sps.nhs.uk/shortages/discontinuation-of-liraglutide-victoza-6mg-ml-solution-for-injection/),
Liraglutide (Victoza®) 6mg/ml solution for injection in a pre-filled pen (licensed in the UK for use in type 2 diabetes only) has been discontinued at the end of 2024
| Pack |
|---|
| 2 pre-filled disposable injection |
| 3 pre-filled disposable injection |
Ozempic® and Rybelsus® are licensed in the UK for use in type 2 diabetes only – do not prescribe solely for weight loss. For Ozempic®: for once weekly dosing, one pen (4 doses) = one month’s supply. For Rybelsus®: 30 tablets = 30 days’ supply.
When to use Semaglutide over other GLP1s:
1. In patients with established cardiovascular disease or CV risk
2. Patients with CKD
3. Type 2 with a compelling need to promote weight loss.
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
Tirzepatide -
(Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist)Tirzepatide (Mounjaro ®) Fact Sheet Click Here
For treating type 2 diabetes in line with NICE TA924. For specialist initiation with specialist defined as secondary care prescribers, GPs, Specialist DSNs, and specialist pharmacists or nurses in primary care (e.g. practice or spoke nurses) who have completed PITstop or equivalent.
For Mounjaro®: for once weekly dosing, one pen (4 doses) = one month’s supply
- Prescribing tirzepatide for weight loss is not clinically supported or funded by Kent and Medway ICB until NICE have evaluated its use for this indication.
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only